Table 1.

Baseline demographics and clinical characteristics by patient

Pt	Sex	Age, years	Race	ECOG PS	Histology	Grade	Stage	Alteration	Testing platforma	Previous lines of therapyb	Sites of metastasis
HER2 amplification and/or overexpression: treated with pertuzumab + trastuzumab
1	M	59	White	0	Salivary duct adenocarcinoma	G3	IV	HER2 amplification	NGS (copy number = 15)	1	Brain, lung, LN
2	M	80	White	1	Adenocarcinoma	G2	IVA	HER2 overexpression	IHC (3+)	1	Bone, LN
3	M	55	Black/African American	2	Unspecified carcinoma	G3	IVA	HER2 amplification + overexpression	FISH/CISH (ratio = 7.3), IHC (3+)	2	Bone, lung, LN
4	M	70	White	1	Invasive ductal carcinoma	G4	IV	HER2 amplification + overexpression	FISH/CISH (ratio = 2.4), IHC (3+)	1	Bone, liver, LN
5	M	73	White	1	Adenocarcinoma	G3	IV	HER2 amplification + overexpression	FISH/CISH (ratio = 9.9), IHC (3+)	1	Bone, LN, spleen
6	M	47	White	1	Adenocarcinoma	G3	IVC	HER2 amplification, overexpression + mutation	NGS (copy number gain; L755F and D769H mutations), IHC (3+)	0	Bone, LN
7	M	61	White	1	Unspecified carcinoma	G3	III	HER2 amplification + overexpression	NGS (copy number = 94); IHC (3+)	0	Liver, lung
8	F	54	White	0	Adenocarcinoma	G3	IV	HER2 amplification + overexpression	NGS (copy number = 104), IHC (3+)	0	Liver, LN
9	M	54	Other	1	Unspecified carcinoma	G3	III	HER2 amplification + mutation	FISH/CISH (ratio = 5.5), NGS (G776V mutation)	0	Bone, lung, LN
10	F	75	Asian	0	Adenocarcinoma	G3	IVA	HER2 amplification	NGS (copy number gain)	0	Lung
11	M	70	White	1	Unspecified carcinoma	G1	IVC	HER2 amplification	NGS (copy number = 60)	2	Bone, liver, lung, LN, intraorbital
12	M	37	White	1	Adenocarcinoma	GX	IV	HER2 overexpression	IHC (3+)	1	Bone, liver
13	M	62	American Indian or Alaska native	1	Mucoepidermoid carcinoma	G3	III	HER2 amplification + overexpression	FISH/CISH (ratio = 7.8), NGS (copy number = 20), IHC (3+)	3	Adrenal gland, liver, lung, LN
14	M	48	Asian	1	Invasive ductal carcinoma	G4	IVA	HER2 amplification + overexpression	FISH/CISH (ratio = 7.2), IHC (3+)	1	Brain, lung, LN
15	F	44	White	2	Adenocarcinoma	G3	IV	HER2 amplification	NGS (copy number = 15)	2	Brain, chest wall, left eye, liver, LN, neck (subcutaneous tissue), parapharyngeal mucosa
HER2 mutation: treated with pertuzumab + trastuzumab
16	M	68	White	0	Adenocarcinoma	G3	III	HER2 mutation	NGS (S310F mutation)	0	Lung, LN, mediastinum
Hh alteration: treated with vismodegib
17	M	65	White	0	Mucoepidermoid carcinoma	G3	II	Hh alteration	NGS (PTCH-1 Q400* mutation)	0	Lung
BRAF V600 mutation: treated with vemurafenib
18	M	51	White	1	Mucoepidermoid carcinoma	G3	IV	BRAF mutation	NGS (V600E mutation)	1	Liver, lung, LN
High TMB: treated with atezolizumab
19	M	82	White	1	Mucoepidermoid carcinoma	G3	IVA	High TMB	NGS (31 mutations/Mb)	0	Adrenal gland, LN, skin

ECOG PS, Eastern Cooperative Oncology Group performance status; F, female; FISH/CISH, fluorescence/chromogenic in situ hybridization; HER2, human epidermal growth factor receptor 2; Hh, Hedgehog; IHC, immunohistochemistry; LN, lymph node; M, male; NGS, next-generation sequencing; Pt, patient; PTCH-1, patched homolog-1; TMB, tumor mutational burden.

^aNot all patients were tested with all testing methods. Details from testing results are included, where available.

^bPrevious regimens consisted of systemic chemotherapy in all patients.